Mizuho reiterates Humana stock rating after earnings beat
Mizuho reiterated a Neutral rating and $495 price target on Humana (HUM) after its Q3 earnings beat estimates. Humana reported a smaller-than-expected loss and raised its 2026 EPS guidance to at least $9.50. The company saw 25% Medicare Advantage membership growth and shares have surged 147% from March lows. Jefferies also reiterated a Buy rating with a $420 target, citing better-than-expected Insurance Medical Loss Ratio results.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise could trigger buying interest and lift the health‑insurance sector.
Market read
Fresh earnings data and guidance lift for a large‑cap insurer provide a clear trading catalyst.
What to watch
Potential regulatory changes to Medicare Advantage reimbursement could temper upside.
Background
Humana is a major U.S. health insurer with a growing Medicare Advantage business.
Ticker impact
Humana reported a Q3 EPS loss of $0.70 beating estimates and raised its 2026 adjusted EPS guidance to at least $9.50.
likely upward pressure as investors price in higher earnings outlook
The earnings beat and guidance lift are fresh primary disclosures for a large‑cap insurer, indicating improved profitability and cost trends.
Market effects
Health insurance sector may see broader optimism as Humana's cost‑trend improvements could lift peers.
U.S. healthcare stocks could benefit from the positive earnings surprise.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
If Medicare Advantage enrollment growth slows, the guidance may be overly optimistic.
Key entities
- companyHumana Inc.
U.S. health insurer reporting Q3 results.
- analystMizuho
Reiterated Neutral rating and $495 price target.
